VERA RUZANOVA1, ANASTASIA PROSKURINA1, GENRIKH RITTER1, EVGENIYA DOLGOVA1, SOFYA OSHIKHMINA1,2, SVETLANA KIRIKOVICH1, EVGENIY LEVITES1, YAROSLAV EFREMOV2,3, OLEG TARANOV4, ALEXANDR OSTANIN5, ELENA CHERNYKH5, NIKOLAY KOLCHANOV6, SERGEY BOGACHEV1,*
Oncology Research, Vol.33, No.5, pp. 1229-1248, 2025, DOI:10.32604/or.2025.059411
- 18 April 2025
Abstract Objectives: Currently, there exist two approaches to the treatment of malignant neoplasms: the Karanahan technology and in situ vaccination, which are based on chronometric delivery of therapeutic agents to the tumor depending on the characteristics of tumor cells, as well as the immune status. The main purpose of this study was to experimentally prove the feasibility of combining the Karanahan technology and in situ vaccination with αOX40 antibodies into a single therapeutic platform to achieve a potent additive antitumor therapeutic effect. Methods: BALB/c mice grafted with B-cellular lymphoma A20 were treated using the Karanahan technology consisting of… More >